Volv Global at WODC Europe 2025 – Where Technology Meets Human

Volv Global sits at the crucial intersection between technology and human beings, i.e., patients and physicians, supporting favourable patient journeys and outcomes.  We use each World Orphan Drug Congress as our touchpoint with the rare disease community, in particular as an opportunity to learn and share with everyone in rare disease, from patients and patient advocacy organisations, to physicians and healthcare providers, to pharma companies, to policy makers and regulators.

 

Volv Global Panel: Bridging the Unbridgeable – Clinical Expertise vs. Real-World Data

Building on Volv Global’s long-running series of workshops talks and panel discussions which move the theme on, year-to-year, this year the focus is on the core value that Every Individual Matters. This panel explores how clinical expertise and real-world data can be united to accelerate rare disease research and care – a real-world example of “Where technology meets Human.” Using the Sanofi–Volv Fabry digital natural history project as a case example, experts from industry, patients, regulators and healthcare providers discuss how to turn dialogue into action – advancing earlier diagnosis, better trial design, and improved patient outcomes.

Panel:

• Fabienne Bartoli, Inspector General, French National Authority for Health
• Charlie Aardewijn, researcher and patient-voice advocate, VU Amsterdam/FSIGN
• Hanka Dekker, Executive Director, VKS, the Dutch patient organisation for inherited metabolic diseases
• Andres Rondon, RWE Portfolio Head – Clinical Development, Sanofi
• Léon Van Wouwe, Clinical Innovation Director, Volv Global

 

 

Christopher Rudolf, CEO of Volv Global, on the Keynote Stage

Our Founder and Chief Executive Officer, Christopher Rudolf, will contribute his expertise to two keynote panels at the World Orphan Drug Congress Europe 2025:

• “Driving Patient-Centric Innovation: Pharma’s Involvement and Stakeholder Collaboration” – 16.50 on Tuesday, 28th October.
• “Leveraging new technology for smarter decision-making in Rare Disease drug development and access” – 09:00 on Wednesday, 29th October.

 

These discussions will highlight how data and technology can empower better decisions across the rare disease ecosystem.

 

Where to Find Volv Global at WODC 2025

Come meet our team directly at Booth #10.200 throughout the congress. We’ll be available for conversations, demos, and discussions on how technology can create meaningful patient impact.

 

 

Looking Back: Volv Global at WODC Europe 2024

At Volv Global, we use each World Orphan Drug Congress as our touchpoint with the rare disease community, in particular as an opportunity to learn and share with everyone in rare disease, from patients and patient advocacy organisations, to physicians and healthcare providers, to pharma companies, to policy makers and regulators.

As we gear up for WODC Europe 2025, here’s a look back at last year’s, in Barcelona, where we ran a workshop on creating real impact for rare disease patients together with participants representing patients and physicians, healthcare providers and healthcare authorities: Our journey to solving complexity throughout the healthcare ecosystem to create real impact for rare disease patients

 

Join Us in Amsterdam : Let’s Talk Rare Disease Innovation

We’re excited to continue our dialogue with the rare disease community at WODC Europe 2025. If you would like to book a meeting with our team during the event, please contact us here.

We look forward to seeing you in Amsterdam this October.

Meet us at the World Orphan Drug Congress Europe 2025 in Amsterdam, 27th-29th October, to find out more.

 

---

FAQ

Q: What is the World Orphan Drug Congress Europe 2025?
A: It’s one of the largest global events bringing together rare disease stakeholders, including patients, pharma, regulators, and technology providers, taking place in Amsterdam from October 27–29, 2025.

Q: Where will Volv Global be at WODC 2025?
A: You can meet us at Booth #10.200 and join our panel sessions on leveraging real-world data and new technologies for rare disease innovation.

Q: Who from Volv Global will be speaking?
A: Christopher Rudolf, CEO, will join two keynote panels, including “Leveraging new technology for smarter decision-making in Rare Disease drug development and access.” Léon Van Wouwe, Clinical Innovation Director, will lead the panel “Bridging the Unbridgeable – Clinical Expertise vs. Real-World Data”

Q: How can I get discounted tickets for WODC 2025?
A: As a Gold Sponsor, Volv Global provides a limited number of discounted tickets for clients and partners. Contact us directly to request one.

Q: How do I book a meeting with Volv Global at the congress?
A: Simply use our contact form to schedule a meeting with our team in advance.

Q: When and where is the World Orphan Drug Congress Europe 2025 taking place?
A: The event will be held at the RAI Amsterdam, Netherlands, from October 27 to 29, 2025.

Q: Why is the World Orphan Drug Congress important for the rare disease community?
A: WODC Europe is one of the key global forums where patients, advocacy groups, researchers, pharma companies, and regulators connect to share insights and shape the future of rare disease treatment and access.

Q: What topics will be covered at the World Orphan Drug Congress Europe 2025?
A: The congress covers orphan drug development, access, regulatory frameworks, patient engagement, and the use of technology such as AI and real-world data in rare disease research.

Q: What is Volv Global’s expertise in rare disease innovation?
A: Volv Global specializes in using advanced data-science and machine learning to map patient journeys, reduce diagnosis delays, and generate real-world evidence that informs clinical development and care optimization.

Q: How can I follow Volv Global’s updates during WODC 2025?
A: You can follow our LinkedIn page and visit our website for live updates, event highlights, and insights shared during the congress.